RESUMO
Despite the long history of investigations of adrenergic compounds and their biological effects, specific mechanisms of their action in distinct compartments of the motor unit remain obscure. Recent results have suggested that not only skeletal muscles but also the neuromuscular junctions represent important targets for the action of catecholamines. In this paper, we describe the effects of adrenaline and noradrenaline on the frequency of miniature endplate potentials, the quantal content of the evoked endplate potentials and the kinetics of acetylcholine quantal release in the motor nerve endings of the mouse diaphragm. Noradrenaline and adrenaline decreased the frequency of the spontaneous release of acetylcholine quanta. The effect of noradrenaline was prevented by the ß adrenoreceptor blocker propranolol, whereas the action of adrenaline was abolished by the α adrenoreceptor antagonist phentolamine. Noradrenaline did not alter the quantal content of endplate potentials, while adrenaline suppressed the evoked release of acetylcholine. Blocking the α adrenoreceptors prevented the decrease in quantal secretion caused by adrenaline. Quantal release became more asynchronous under noradrenaline, as evidenced by a greater dispersion of real synaptic delays; in contrast, adrenaline synchronized the release process. Our data suggest an involvement of α and ß adrenoreceptors in the diverse modulation of the frequency of miniature endplate potentials, the quantal content of the evoked endplate potentials and the kinetics of acetylcholine quantal secretion in the mouse neuromuscular junction. Moreover, the adrenoblockers affected both the evoked and spontaneous quantal release of acetylcholine, suggesting the presence of endogenous catecholamines in the vicinity of cholinergic synapses.
Assuntos
Acetilcolina/metabolismo , Epinefrina/fisiologia , Junção Neuromuscular/metabolismo , Norepinefrina/fisiologia , Agonistas alfa-Adrenérgicos/farmacologia , Agonistas Adrenérgicos beta/farmacologia , Animais , Diafragma/fisiologia , Epinefrina/antagonistas & inibidores , Epinefrina/farmacologia , Feminino , Cinética , Masculino , Camundongos , Potenciais Pós-Sinápticos em Miniatura/fisiologia , Norepinefrina/antagonistas & inibidores , Norepinefrina/farmacologia , Fentolamina/farmacologia , Propranolol/farmacologia , Receptores Adrenérgicos alfa/fisiologia , Receptores Adrenérgicos beta/fisiologiaRESUMO
INTRODUCTION: Follistatin (FST) is a protein with numerous biological roles and was recently identified as an exercise-inducible hepatokine; however, the signals that regulate this are not well understood. The purpose of this study was to delineate potential endocrine factors that may regulate hepatic FST at rest and during exercise. METHODS: This study used four experiments. First, male and female C57BL/6J mice remained sedentary or were subjected to a single bout of exercise at moderate or exhaustive intensity with liver collected immediately post. Second, mice were injected with glucagon (1 mg·kg, 60 min), epinephrine (2 mg·kg, 30 min), glucagon then epinephrine, or saline. Third, mice were pretreated with propranolol (20-60 mg·kg, 30 min) before epinephrine injection. Fourth, glucagon receptor wild type (Gcgr) or knockout (Gcgr) mice were pretreated with saline or propranolol (20 mg·kg, 30 min) and were subjected to a single bout of exhaustive exercise with liver collected immediately post or after 2 h recovery. In all experiments liver FST mRNA expression was measured, and in experiment four FST protein content was measured. RESULTS: A single bout of treadmill exercise performed at an exhaustive but not moderate-intensity increased FST expression, as did injection of glucagon or epinephrine alone and when combined. Pretreatment of mice with propranolol attenuated the epinephrine-induced increase in FST expression. The exercise-induced increase in FST expression was attenuated in Gcgr mice, with no effect of propranolol. Gcgr mice had higher protein content of FST, but there was no effect of exercise or propranolol. CONCLUSIONS: These data suggest that both glucagon and epinephrine regulate hepatic FST expression at rest; however, only glucagon is required for the exercise-induced increase.
Assuntos
Epinefrina/fisiologia , Folistatina/metabolismo , Glucagon/fisiologia , Fígado/metabolismo , Condicionamento Físico Animal , Descanso , Antagonistas Adrenérgicos beta/farmacologia , Animais , Epinefrina/administração & dosagem , Epinefrina/antagonistas & inibidores , Feminino , Expressão Gênica , Glucagon/administração & dosagem , Injeções , Masculino , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fosforilação , Propranolol/farmacologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Proteína Smad2/metabolismo , Proteína Smad3/metabolismoAssuntos
Antagonistas Adrenérgicos beta/farmacologia , Proliferação de Células/efeitos dos fármacos , Epinefrina/metabolismo , Neoplasias Pancreáticas/metabolismo , Estresse Psicológico/metabolismo , Antagonistas Adrenérgicos beta/uso terapêutico , Animais , Modelos Animais de Doenças , Epinefrina/antagonistas & inibidores , Humanos , Camundongos , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/mortalidade , Estresse Psicológico/complicações , Taxa de Sobrevida , Resultado do TratamentoRESUMO
We investigated the effect of a new indole derivative Sbt-828 with antiaggregant properties on prostacyclin-generating activity of the vascular wall and thromboxane A2 level in platelets of intact rats. The substance under study did not affect prostacyclin production by the vascular wall and significantly reduced thromboxane A2 level, being superior to the reference drug acetylsalicylic acid by 1.6 times, as seen from reduced malonic dialdehyde level in the thrombin-induced rat platelets.
Assuntos
Plaquetas/efeitos dos fármacos , Epoprostenol/sangue , Indóis/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Tromboxano A2/sangue , Animais , Animais não Endogâmicos , Aorta Abdominal/efeitos dos fármacos , Aorta Abdominal/metabolismo , Aspirina/farmacologia , Plaquetas/citologia , Plaquetas/metabolismo , Epinefrina/antagonistas & inibidores , Epinefrina/farmacologia , Indóis/síntese química , Injeções Intravenosas , Dose Letal Mediana , Masculino , Malondialdeído/sangue , Inibidores da Agregação Plaquetária/síntese química , Ratos , Trombina/antagonistas & inibidores , Trombina/farmacologia , Técnicas de Cultura de TecidosRESUMO
Objective Atorvastatin reduces the incidence of cardiovascular events. However, the effects of atorvastatin on platelet aggregation are unknown. Methods Blood samples were obtained from 126 healthy volunteers. Prepared isolated platelet suspensions were adjusted with saline to three different concentrations of 100 × 109, 300 × 109, and 600 × 109 platelets/L. Platelet samples were incubated with atorvastatin (10-7 mol/L, 10-6 mol/L or 10-5 mol/L), and stimulated with ADP (10 µmol/L), arachidonic acid (0.5 mmol/L), collagen (2 µg/mL), and epinephrine (1 mg/mL). The maximal amplitude of aggregation and the curve slope were measured by electric impedance aggregometry. Results Atorvastatin inhibited platelet aggregation at moderate (300 × 109/L) and high (600 × 109/L) concentrations. However, an inhibitory effect of atorvastatin at low concentrations (100 × 109/L) was not observed. Conclusions The study shows that atorvastatin inhibits platelet aggregation in vitro, and this inhibitory effect is related to platelet concentrations.
Assuntos
Anticolesterolemiantes/farmacologia , Atorvastatina/farmacologia , Plaquetas/efeitos dos fármacos , Coagulantes/antagonistas & inibidores , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Difosfato de Adenosina/farmacologia , Adolescente , Adulto , Ácido Araquidônico/antagonistas & inibidores , Ácido Araquidônico/farmacologia , Plaquetas/citologia , Plaquetas/fisiologia , Contagem de Células , Células Cultivadas , Coagulantes/farmacologia , Colágeno/antagonistas & inibidores , Colágeno/farmacologia , Epinefrina/antagonistas & inibidores , Epinefrina/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária/fisiologiaRESUMO
Catecholamines may undergo iron-promoted oxidation resulting in formation of reactive intermediates (aminochromes) capable of redox cycling and reactive oxygen species (ROS) formation. Both of them induce oxidative stress resulting in cellular damage and death. Iron chelation has been recently shown as a suitable tool of cardioprotection with considerable potential to protect cardiac cells against catecholamine-induced cardiotoxicity. However, prolonged exposure of cells to classical chelators may interfere with physiological iron homeostasis. Prochelators represent a more advanced approach to decrease oxidative injury by forming a chelating agent only under the disease-specific conditions associated with oxidative stress. Novel prochelator (lacking any iron chelating properties) BHAPI [(E)-N-(1-(2-((4-(4,4,5,5-tetramethyl-1,2,3-dioxoborolan-2-yl)benzyl)oxy)phenyl)ethylidene) isonicotinohydrazide] is converted by ROS to active chelator HAPI with strong iron binding capacity that efficiently inhibits iron-catalyzed hydroxyl radical generation. Our results confirmed redox activity of oxidation products of catecholamines isoprenaline and epinephrine, that were able to activate BHAPI to HAPI that chelates iron ions inside H9c2 cardiomyoblasts. Both HAPI and BHAPI were able to efficiently protect the cells against intracellular ROS formation, depletion of reduced glutathione and toxicity induced by catecholamines and their oxidation products. Hence, both HAPI and BHAPI have shown considerable potential to protect cardiac cells by both inhibition of deleterious catecholamine oxidation to reactive intermediates and prevention of ROS-mediated cardiotoxicity.
Assuntos
Compostos de Boro/farmacologia , Cardiotônicos/farmacologia , Catecolaminas/antagonistas & inibidores , Catecolaminas/toxicidade , Quelantes de Ferro/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Semicarbazonas/farmacologia , Animais , Biocatálise , Ácidos Borônicos/farmacologia , Linhagem Celular , Epinefrina/antagonistas & inibidores , Epinefrina/toxicidade , Glutationa/metabolismo , Humanos , Radical Hidroxila/metabolismo , Ferro/química , Isoproterenol/antagonistas & inibidores , Isoproterenol/toxicidade , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Pró-Fármacos/farmacologia , RatosRESUMO
The present study evaluates the in vitro, in vivo, and ex vivo antithrombotic and anticoagulant effect of two flavonoids: quercetin and quercetin-3-O-ß-d-glucoside (isoquercetin). The present results have shown that quercetin and isoquercetin inhibit the enzymatic activity of thrombin and FXa and suppress fibrin clot formation and blood clotting. The prolongation effect of quercetin and isoquercetin against epinephrine and collagen-induced platelet activation may have been caused by intervention in intracellular signaling pathways including coagulation cascade and aggregation response on platelets and blood. The in vivo and ex vivo anticoagulant efficacy of quercetin and isoquercetin was evaluated in thrombin-induced acute thromboembolism model and in ICR mice. Our findings showed that in vitro and in vivo inhibitory effects of quercetin were slightly higher than that of quercetin glucoside, whereas in vitro and ex vivo anticoagulant effects of quercetin were weaker than that of quercetin glucoside because of their structural characteristics.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Fibrinolíticos/farmacologia , Flavonoides/farmacologia , Quercetina/farmacologia , Trombina/antagonistas & inibidores , Tromboembolia/tratamento farmacológico , Doença Aguda , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Plaquetas/patologia , Colágeno/antagonistas & inibidores , Colágeno/farmacologia , Modelos Animais de Doenças , Epinefrina/antagonistas & inibidores , Epinefrina/farmacologia , Fator Xa/metabolismo , Fibrina/antagonistas & inibidores , Fibrina/metabolismo , Glucosídeos , Masculino , Camundongos , Camundongos Endogâmicos ICR , Ativação Plaquetária/efeitos dos fármacos , Cultura Primária de Células , Ratos Sprague-Dawley , Transdução de Sinais , Trombina/administração & dosagem , Tromboembolia/induzido quimicamente , Tromboembolia/metabolismo , Tromboembolia/patologiaRESUMO
Catechol groups can be involved in redox cycling accompanied by generation of reactive oxygen species (ROS) which may lead to oxidative damage of cellular macromolecules including DNA. The objective of this investigation was to evaluate possible genotoxic effects of a natural catecholamine adrenaline in cultured human lymphocytes using cytogenetic (sister chromatid exchange and micronuclei) and the single cell gel electrophoresis (Comet) assay. In cytogenetic tests, six experimental concentrations of adrenaline were used in a range from 0.01-500 µM. There were no indications of genotoxic effects of adrenaline in sister chromatid exchange and micronucleus tests. However, at four highest concentrations of adrenaline (5 µM, 50 µM, 150 µM and 300 µM) we observed a decreased mitotic index and cell-cycle delay. In addition, in the Comet assay we used adrenaline in a range from 0.0005-500 µM, at two treatment times: 15 min or 60 min. In contrast to cytogenetic analysis, there was a dose-dependent increase of DNA damage detected in the Comet assay. These effects were significantly reduced by concomitant treatment with quercetin or catalase. Therefore, the obtained results indicate that adrenaline may exhibit genotoxic effects in cultured human lymphocytes, most likely due to production of reactive oxygen species.
Assuntos
Dano ao DNA/efeitos dos fármacos , Epinefrina/toxicidade , Linfócitos/efeitos dos fármacos , Adulto , Catalase/farmacologia , Ensaio Cometa , Relação Dose-Resposta a Droga , Epinefrina/antagonistas & inibidores , Humanos , Masculino , Testes para Micronúcleos , Quercetina/farmacologia , Troca de Cromátide Irmã/efeitos dos fármacosRESUMO
BACKGROUND/AIMS: Renalase is a recently discovered, kidney-specific monoamine oxidase that metabolizes circulating catecholamines. These findings present new insights into hypertension and chronic kidney diseases. Previous data demonstrated that renalase was mainly secreted from proximal tubules which could be evoked by catecholamines. The purpose of this study is to investigate whether renalase expression is induced by epinephrine via α-adrenoceptor/NFκB pathways. METHODS: HK2 cells were utilized to explore renalase expression in response to epinephrine in vitro. Phentolamine, an α-adrenoceptor antagonist, and Tosyl Phenylalanyl Chloromethyl Ketone (TPCK) were used to block α-adrenoceptor and to knock down the transcription factor NFκB, respectively. Renalase expression was analyzed using Western blot and quantitative PCR. RESULTS: Both protein and mRNA levels of renalase in HK2 cells increased in response to epinephrine (P<0.05). Epinephrine-evoked renalase expression was attenuated by phentolamine and TPCK separately (P<0.05). CONCLUSION: Epinephrine evokes renalase secretion via α-adrenoceptor/NF-κB pathways in renal proximal tubular epithelial cells.
Assuntos
Agonistas alfa-Adrenérgicos/farmacologia , Epinefrina/farmacologia , Células Epiteliais/metabolismo , Túbulos Renais Proximais/metabolismo , Monoaminoxidase/metabolismo , NF-kappa B/efeitos dos fármacos , Receptores Adrenérgicos alfa/efeitos dos fármacos , Antagonistas Adrenérgicos alfa/farmacologia , Linhagem Celular , Epinefrina/antagonistas & inibidores , Células Epiteliais/efeitos dos fármacos , Humanos , Túbulos Renais Proximais/citologia , Túbulos Renais Proximais/efeitos dos fármacos , Fentolamina/farmacologia , Inibidores da Síntese de Proteínas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Tosilfenilalanil Clorometil Cetona/farmacologiaRESUMO
This study investigated whether or not the anesthetic effect of ketamine in rats is dependent on adrenal gland hormones. The study was performed on two main rat groups, intact and adrenalectomized. Rat were divided into subgroups and given appropriate doses of ketamine, metyrapone or metyrosine. Durations of anesthesia in the groups were then recorded. Endogenous catecholamine levels were measured in samples taken from peripheral blood. This experimental results showed that ketamine did not induce anesthesia in intact rats at doses of 15 or 30mg/kg, and that at 60mg/kg anesthesia was established for only 11min. However, ketamine induced significant anesthesia even at a dose of 30mg/kg in animals in which production of endogenous catecholamine (adrenalin, noradrenalin dopamine) was inhibited with metyrosine at a level of 45-47%. Ketamine at 60mg/kg in animals in which endogenous catecholamine was inhibited at a level of 45-47% established anesthesia for 47.6min. However, ketamine at 30 and 60mg/kg induced longer anesthesia in adrenalectomized rats with higher noradrenalin and dopamine levels but suppressed adrenalin production. Adrenalin plays an important role in the control of duration of ketamine anesthesia, while noradrenalin, dopamine and corticosterone have no such function. If endogenous adrenalin is suppressed, ketamine can even provide sufficient anesthesia at a 2-fold lower dose. This makes it possible for ketamine to be used in lengthy surgical procedures.
Assuntos
Anestésicos Dissociativos/administração & dosagem , Epinefrina/antagonistas & inibidores , Ketamina/administração & dosagem , Adrenalectomia , Animais , Relação Dose-Resposta a Droga , Epinefrina/fisiologia , Masculino , Ratos , Ratos WistarRESUMO
The nasal mucosa is very vascular, receiving more blood flow per cubic centimeter of tissue than does muscle, brain or liver (Drettner and Aust, 1974; [1]). This vascularity can present a major problem during sinus surgery. Surgeons routinely use topical vasoconstrictors in endoscopic sinus surgery however, the optimal regimen is not clear. Imidazoline nasal sprays are often used up to 1hour before sinonasal surgery to aid in intraoperative vasoconstriction. After the induction of anaesthesia, epinephrine-based topical and submucosal preparations are subsequently administered to further enhance vasoconstriction. Imidazolines are non-selective, partial alpha adrenoceptor agonists with a higher affinity, yet lower potency, for alpha adrenoceptors when compared to epinephrine. It is hypothesized that imidazolines block the action of epinephrine on the alpha adrenoceptors of the nasal mucosa resulting in less vasoconstriction, and a poorer intra-operative field, when compared to the use of epinephrine alone. This paper hypothesizes that preoperative imidazoline administration may adversely affect optimal intra-operative vasoconstriction.
Assuntos
Imidazolinas/farmacologia , Mucosa Nasal/irrigação sanguínea , Seios Paranasais/cirurgia , Vasoconstrição/efeitos dos fármacos , Agonistas alfa-Adrenérgicos/farmacologia , Epinefrina/antagonistas & inibidores , Humanos , Imidazolinas/efeitos adversos , Modelos Biológicos , Mucosa Nasal/cirurgiaRESUMO
BACKGROUND: There is both clinical and experimental evidence to support the application of corticosterone in the management of inflammation and pain. Corticosterone has been used to treat painful inflammatory diseases and can produce antinociceptive effects. Epinephrine is synthesized from norepinephrine by the enzyme phenylethanolamine N-methyltransferase (PNMT) and works as an endogenous adrenoceptor ligand secreted peripherally by the adrenal medulla. It is currently unclear whether corticosterone's antinociceptive effect is associated with the modulation of peripheral epinephrine. METHODS: We first determined whether exogenous corticosterone treatment actually produced an antinociceptive effect in a formalin-induced pain model, and then examined whether this corticosterone-induced antinociceptive effect was altered by suppression of adrenal-derived epinephrine, using the following three suppression methods: (1) inhibition of the PNMT enzyme; (2) blocking peripheral epinephrine receptors; and (3) adrenalectomy. RESULTS: Exogenous treatment with corticosterone at a high dose (50 mg/kg), but not at lower doses (5, 25 mg/kg), significantly reduced pain responses in the late phase. Moreover, injection of 2,3-dichloro-a-methylbenzylamine, a PNMT enzyme inhibitor, (10 mg/kg) before corticosterone treatment caused a leftward shift in the dose-response curve for corticosterone and injection of propranolol (5 mg/kg), but not phentolamine, also shifted the dose-response curve to the left during the late phase. Chemical sympathectomy with 6-hydroxydopamine had no effect on corticosterone-induced antinociceptive effect, but injection of a low dose of corticosterone produced an antinociceptive effect in adrenalectomized animals. CONCLUSIONS: These results demonstrate that suppression of epinephrine, derived from adrenal gland, enhances the antinociceptive effect of exogenous corticosterone treatment in an inflammatory pain model.
Assuntos
Glândulas Suprarrenais/efeitos dos fármacos , Glândulas Suprarrenais/metabolismo , Anti-Inflamatórios/farmacologia , Corticosterona/farmacologia , Epinefrina/antagonistas & inibidores , Medição da Dor/efeitos dos fármacos , Glândulas Suprarrenais/cirurgia , Adrenalectomia , Animais , Relação Dose-Resposta a Droga , Epinefrina/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos ICR , Medição da Dor/psicologia , Feniletanolamina N-Metiltransferase/antagonistas & inibidores , Receptores Adrenérgicos/efeitos dos fármacos , Simpatectomia QuímicaRESUMO
BACKGROUND: Epinephrine was recently shown to induce a hypotension episode. Activation of ß2-adrenoceptors with smooth muscle relaxation may be the underlying mechanism. This study investigated the effects of ICI 118551, a ß2-adrenoceptors antagonist, on epinephrine-induced blood pressure reduction via different administration routes in rats. METHODS: A total of 144 Sprague Dawley rats were equally randomized into 3 groups (intranasal, intravenous, and intra-arterial administration), each with 4 subgroups: saline + saline, ICI 118551 + saline, saline + epinephrine, and ICI 118551 + epinephrine. All rats were anesthetized while spontaneously breathing. Epinephrine was administered at doses of 5 µg/kg via nose, 0.25 µg/kg via femoral vein, and 0.1 µg/kg via aorta. Mean arterial pressure and heart rate were monitored. RESULTS: Mean arterial pressure decreased in all 3 saline + epinephrine subgroups after administration (P < 0.05), whereas it did not in other subgroups. Heart rate had no significant change in all subgroups. CONCLUSIONS: Epinephrine-induced blood pressure reduction can be prevented by ICI 118551 in rats, suggesting that the activation of ß2-adrenoceptors contributes to blood pressure reduction.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Anti-Hipertensivos/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Epinefrina/administração & dosagem , Administração Intranasal , Agonistas de Receptores Adrenérgicos beta 2/efeitos adversos , Agonistas de Receptores Adrenérgicos beta 2/química , Antagonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Animais , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/antagonistas & inibidores , Aorta Torácica , Epinefrina/efeitos adversos , Epinefrina/antagonistas & inibidores , Veia Femoral , Frequência Cardíaca/efeitos dos fármacos , Hipotensão/induzido quimicamente , Hipotensão/prevenção & controle , Infusões Intra-Arteriais , Infusões Intravenosas , Masculino , Propanolaminas/uso terapêutico , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Receptores Adrenérgicos beta 2/química , Receptores Adrenérgicos beta 2/metabolismoRESUMO
Epinephrine and norepinephrine are produced during psychological stress and can directly bind to cells to induce DNA damage. These effects may have more long-lasting consequences such as DNA mutations resulting in an increased potential for cellular transformation and/or tumor progression. This study examined the molecular effects of a chronic (24 h) in vitro exposure to these stress hormones on murine 3T3 cells. Long exposures (24 h) in dose-response experiments with norepinephrine or epinephrine induced significant increases in DNA damage in treated cells compared to that of untreated controls as measured by the alkaline comet assay. Pre-treatment with a blocking agent (the ß-adrenergic receptor antagonist propranolol) eliminated this increase in damage. In addition, both norepinephrine and epinephrine increased cellular transformation, as assessed by growth in soft agar, and 3T3 cells pre-treated with either norepinephrine or epinephrine induced a more rapid onset of tumors and more aggressive tumor growth in nude mice. In summary, incubation of 3T3 cells with catecholamines results in long-term DNA damage as measured by increased transformed phenotypes and tumor progression, indicating that they are important mediators of stress effects on genomic instability and vulnerability to tumor formation.
Assuntos
Transformação Celular Neoplásica/efeitos dos fármacos , Epinefrina/toxicidade , Norepinefrina/toxicidade , Estresse Psicológico/fisiopatologia , Antagonistas Adrenérgicos beta/farmacologia , Animais , Testes de Carcinogenicidade , Ensaio Cometa , DNA/efeitos dos fármacos , Dano ao DNA , Progressão da Doença , Relação Dose-Resposta a Droga , Epinefrina/antagonistas & inibidores , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Células NIH 3T3 , Norepinefrina/antagonistas & inibidores , Propranolol/farmacologiaRESUMO
BACKGROUND: Previous studies indicate epinephrine adversely affects arterial oxygenation when administered in a rat model of local anesthetic overdose. The authors tested whether epinephrine alone exerts similar effects in the intact animal. METHODS: Anesthetized rats received a single intravenous injection of epinephrine (25, 50, or 100 mcg/kg); matched cohorts were pretreated with phentolamine (100 mcg/kg); n = 5 for each of the six treatment groups. Arterial pressure and blood gases were measured at baseline, 1 and 10 min after epinephrine administration. Pulmonary capillary pressures during epinephrine infusion with normal and increased flows were measured in an isolated lung preparation. RESULTS: Epinephrine injection in the intact animal caused hypoxemia, hypercapnia, and acidosis at all doses. Arterial oxygen tension was reduced within 1 min of injection. Hyperlactatemia occurred by 10 min after 50 and 100 mcg/kg. Rate pressure product was decreased by 10 min after 100 mcg/kg epinephrine. Pretreatment with phentolamine attenuated these effects except at 100 mcg/kg epinephrine. In the isolated lung preparation, epinephrine in combination with increased pulmonary flow increased pulmonary capillary pressure and lung water. CONCLUSIONS: Bolus injection of epinephrine in the intact, anesthetized rat impairs pulmonary oxygen exchange within 1 min of treatment. Effects were blunted by α-adrenergic receptor blockade. Edema occurred in the isolated lung above a threshold pulmonary capillary pressure when epinephrine treatment was coupled with an increase in pulmonary flow. These results potentially argue against using traditional doses of epinephrine for resuscitation, particularly in the anesthetized patient.
Assuntos
Anestesia , Epinefrina/farmacologia , Consumo de Oxigênio/efeitos dos fármacos , Circulação Pulmonar/efeitos dos fármacos , Troca Gasosa Pulmonar/efeitos dos fármacos , Pressão Propulsora Pulmonar/efeitos dos fármacos , Vasoconstritores/farmacologia , Antagonistas Adrenérgicos alfa/farmacologia , Animais , Pressão Arterial/efeitos dos fármacos , Gasometria , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Epinefrina/antagonistas & inibidores , Hemodinâmica/efeitos dos fármacos , Técnicas In Vitro , Pulmão/efeitos dos fármacos , Masculino , Tamanho do Órgão/fisiologia , Fentolamina/farmacologia , Ratos , Ratos Sprague-Dawley , Vasoconstritores/antagonistas & inibidoresRESUMO
Pomolic acid (PA), triterpenoid isolated from Licania pittieri, has previously shown a potent ability to inhibit adenosine diphosphate (ADP)- and epinephrine-induced human platelet aggregation. To investigate whether PA could be an antagonist of ADP-activated receptors of human platelets (P2Y(1) and P2Y(12)), pharmacological studies were conducted to examining its ability to modulate the platelet shape change induced by a selective P2Y(1) receptor agonist MRS2365 and also the nature of its possible interaction with ADP receptors by analyzing the characteristics of log concentration-response curves of ADP constructed in the absence and in the presence of fixed concentrations of PA, using in vitro platelet aggregation assays. PA did not interfere with the activation of P2Y(1) receptor by MRS2365 to induce platelet shape change and displayed a competitive antagonism of ADP-induced platelet aggregation, which most probably involves competition for a single binding site in platelets. The estimated equilibrium dissociate constant (K(b)) of PA as ADP receptor antagonist was 15.4±0.06nM. Together, these findings give indirect evidence for the idea that PA could be a potent competitive antagonist of P2Y(12) receptor, and open the possibility to consider it as new member of the non-nucleotide generation of antiplatelet drugs.
Assuntos
Difosfato de Adenosina/antagonistas & inibidores , Chrysobalanaceae/química , Ácido Oleanólico/análogos & derivados , Agregação Plaquetária/efeitos dos fármacos , Avaliação de Medicamentos , Epinefrina/antagonistas & inibidores , Humanos , Técnicas In Vitro , Ácido Oleanólico/farmacologia , Fitoterapia , Folhas de Planta/química , Inibidores da Agregação Plaquetária/farmacologiaRESUMO
This study investigates α(2)-adrenergic receptor (α(2)AR) mediated feedback inhibition of catecholamine release from the adrenal medulla of adult (52 weeks) and old (98 weeks) spontaneously hypertensive rats (SHR) and normotensive controls Wistar Kyoto (WKY) rats. Adrenal epinephrine content as well as the spontaneous and the nicotinic-evoked release of epinephrine were similar between adult SHR and WKY rats. Aging produced a significant reduction in epinephrine synthesis in WKY rats. In contrast, in SHR aging produced a significant increase in epinephrine release without significant changes in epinephrine synthesis. The α(2)AR agonist medetomidine abolished (80-90% inhibition) the nicotinic-evoked release of epinephrine in adult SHR and WKY rats. With aging, this effect was unaltered in WKY rats but was significantly decreased in SHR (30% inhibition). Adrenal α(2A)AR mRNA levels were significantly reduced in old SHR compared with age matched WKY rats. In conclusion, in aging the α(2)AR mediated feedback inhibition of epinephrine release from the adrenal medulla is preserved in WKY rats but compromised in SHR, resulting in increased epinephrine release.
Assuntos
Envelhecimento/fisiologia , Hipertensão/metabolismo , Hipertensão/fisiopatologia , Receptores Adrenérgicos alfa 2/fisiologia , Envelhecimento/metabolismo , Envelhecimento/patologia , Animais , Epinefrina/antagonistas & inibidores , Epinefrina/biossíntese , Epinefrina/metabolismo , Retroalimentação Fisiológica , Masculino , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Receptores Adrenérgicos alfa 2/genéticaRESUMO
To understand the physiological role of ghrelin, it is crucial to study both the actions of ghrelin and the regulation of ghrelin secretion. Although ghrelin actions have been extensively revealed, the direct factors regulating ghrelin secretion by ghrelin-producing cells (X/A-like cells), however, is not fully understood. In this study, we examined the effects of peptide hormones and neurotransmitters on in vitro ghrelin secretion by the recently developed ghrelin-producing cell line MGN3-1. Oxytocin and vasopressin significantly stimulated ghrelin secretion by MGN3-1 cells. Because MGN3-1 cells express only oxytocin receptor mRNA, not vasopressin receptor mRNA, oxytocin is the likely regulator, with the effect of vasopressin mediated by a cross-reaction. We also discovered that dopamine stimulates ghrelin secretion from MGN3-1 cells in a similar manner to the previously known ghrelin stimulators, epinephrine and norepinephrine. MGN3-1 cells expressed mRNA encoding dopamine receptors D1a and D2. The dopamine receptor D1 agonist fenoldopam stimulated ghrelin secretion, whereas the D2, D3 agonist bromocriptine did not. Furthermore, the D1 receptor antagonist SKF83566 attenuated the stimulatory effect of dopamine. These results indicate that the stimulatory effect of dopamine on ghrelin secretion is mediated by the D1a receptor. In conclusion, we identified two direct regulators of ghrelin, oxytocin and dopamine. These findings will provide new direction for further studies seeking to further understand the regulation of ghrelin secretion, which will in turn lead to greater understanding of the physiological role of ghrelin.
Assuntos
Dopamina/metabolismo , Células Secretoras de Gastrina/metabolismo , Grelina/metabolismo , Ocitocina/metabolismo , Receptores de Dopamina D1/metabolismo , Receptores de Ocitocina/metabolismo , Antagonistas de Receptores Adrenérgicos beta 1/farmacologia , Animais , Linhagem Celular , Agonistas de Dopamina/farmacologia , Antagonistas de Dopamina/farmacologia , Epinefrina/antagonistas & inibidores , Epinefrina/metabolismo , Células Secretoras de Gastrina/efeitos dos fármacos , Regulação da Expressão Gênica , Grelina/genética , Antagonistas de Hormônios/farmacologia , Camundongos , Norepinefrina/antagonistas & inibidores , Norepinefrina/metabolismo , Ocitocina/antagonistas & inibidores , RNA Mensageiro/metabolismo , Receptores Adrenérgicos beta 1/genética , Receptores Adrenérgicos beta 1/metabolismo , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/antagonistas & inibidores , Receptores de Dopamina D1/genética , Receptores de Ocitocina/antagonistas & inibidores , Receptores de Ocitocina/genética , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
The present study was designed to examine the effects of circulating catecholamines released by sympathoadrenal system on the haemodynamics of the masseter muscle in deeply urethane-anaesthetized, artificially ventilated, cervically vagotomized and sympathectomized rats. Intravenous administration of adrenaline induced a biphasic change of blood flow in the masseter muscle (MBF). The change of blood flow showed an initial marked increase and successive slight decrease in a dose-dependent manner (0.01-1 microg/kg). The administration of noradrenaline had no significant effect on the MBF. The increase in the MBF evoked by exogenously applied adrenaline was markedly reduced by the intravenous administration of propranolol (100 microg/kg), whereas pretreatment with either hexamethonium (10 mg/kg), atropine (100 microg/kg), or phentolamine (1 mg/kg) failed to affect the MBF increase. Electrical stimulation of splanchnic nerve (SPLN) preganglionic neurones projecting to the adrenal medulla elicited frequency-dependent (1-20 Hz) increases in the MBF. The intravenous administration of the beta(2)-adrenergic receptor selective antagonist, ICI 118551 (0.5 mg/kg), almost abolished the MBF increase induced by SPLN stimulation, but pretreatment with the beta(1)-adrenergic receptor selective antagonist, atenolol (1 mg/kg), had no effect on this response. The results of the present study indicate that circulating adrenaline elicits acute vasodilatation through a beta-adrenergic mechanism in the rat masseter muscle. Vascular beta(2)-adrenergic receptors in the masseter muscle may be activated preferentially by adrenaline released from the adrenal medulla, suggesting that the sympathoadrenal system is involved in the marked MBF increase during sympathoexcitation.
Assuntos
Agonistas Adrenérgicos/farmacologia , Epinefrina/farmacologia , Músculo Masseter/irrigação sanguínea , Simpatomiméticos/farmacologia , Vasoconstritores/farmacologia , Medula Suprarrenal/fisiologia , Agonistas Adrenérgicos/administração & dosagem , Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Animais , Atropina/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Estimulação Elétrica , Epinefrina/administração & dosagem , Epinefrina/antagonistas & inibidores , Bloqueadores Ganglionares/farmacologia , Hexametônio/farmacologia , Injeções Intravenosas , Nervo Lingual/fisiologia , Masculino , Músculo Masseter/efeitos dos fármacos , Vias Neurais/fisiologia , Fentolamina/farmacologia , Propanolaminas/farmacologia , Propranolol/farmacologia , Ratos , Fluxo Sanguíneo Regional/efeitos dos fármacos , Nervos Esplâncnicos/fisiologia , Simpatectomia , Simpatomiméticos/administração & dosagem , Simpatomiméticos/antagonistas & inibidores , Vagotomia , Vasoconstritores/administração & dosagem , Vasoconstritores/antagonistas & inibidores , Vasodilatadores/farmacologiaRESUMO
BACKGROUND: Stress, both acute and chronic, can impair cutaneous wound repair, which has previously been mechanistically ascribed to stress-induced elevations of cortisol. Here we aimed to examine an alternate explanation that the stress-induced hormone epinephrine directly impairs keratinocyte motility and wound re-epithelialization. Burn wounds are examined as a prototype of a high-stress, high-epinephrine, wound environment. Because keratinocytes express the beta2-adrenergic receptor (beta2AR), another study objective was to determine whether beta2AR antagonists could block epinephrine effects on healing and improve wound repair. METHODS AND FINDINGS: Migratory rates of normal human keratinocytes exposed to physiologically relevant levels of epinephrine were measured. To determine the role of the receptor, keratinocytes derived from animals in which the beta2AR had been genetically deleted were similarly examined. The rate of healing of burn wounds generated in excised human skin in high and low epinephrine environments was measured. We utilized an in vivo burn wound model in animals with implanted pumps to deliver beta2AR active drugs to study how these alter healing in vivo. Immunocytochemistry and immunoblotting were used to examine the up-regulation of catecholamine synthetic enzymes in burned tissue, and immunoassay for epinephrine determined the levels of this catecholamine in affected tissue and in the circulation. When epinephrine levels in the culture medium are elevated to the range found in burn-stressed animals, the migratory rate of both cultured human and murine keratinocytes is impaired (reduced by 76%, 95% confidence interval [CI] 56%-95% in humans, p < 0.001, and by 36%, 95% CI 24%-49% in mice, p = 0.001), and wound re-epithelialization in explanted burned human skin is delayed (by 23%, 95% CI 10%-36%, p = 0.001), as compared to cells or tissues incubated in medium without added epinephrine. This impairment is reversed by beta2AR antagonists, is absent in murine keratinocytes that are genetically depleted of the beta2AR, and is reproduced by incubation of keratinocytes with other beta2AR-specific agonists. Activation of the beta2AR in cultured keratinocytes signals the down-regulation of the AKT pathway, accompanied by a stabilization of the actin cytoskeleton and an increase in focal adhesion formation, resulting in a nonmigratory phenotype. Burn wound injury in excised human skin also rapidly up-regulates the intra-epithelial expression of the epinephrine synthesizing enzyme phenylethanolamine-N-methyltransferase, and tissue levels of epinephrine rise dramatically (15-fold) in the burn wounded tissue (values of epinephrine expressed as pg/ug protein +/- standard error of the mean: unburned control, 0.6 +/- 0.36; immediately postburn, 9.6 +/- 1.58; 2 h postburn, 3.1 +/- 1.08; 24 h post-burn, 6.7 +/- 0.94). Finally, using an animal burn wound model (20% body surface in mice), we found that systemic treatment with betaAR antagonists results in a significant increase (44%, 95% CI 27%-61%, p < 0.00000001) in the rate of burn wound re-epithelialization. CONCLUSIONS: This work demonstrates an alternate pathway by which stress can impair healing: by stress-induced elevation of epinephrine levels resulting in activation of the keratinocyte beta2AR and the impairment of cell motility and wound re-epithelialization. Furthermore, since the burn wound locally generates epinephrine in response to wounding, epinephrine levels are locally, as well as systemically, elevated, and wound healing is impacted by these dual mechanisms. Treatment with beta adrenergic antagonists significantly improves the rate of burn wound re-epithelialization. This work suggests that specific beta2AR antagonists may be apt, near-term translational therapeutic targets for enhancing burn wound healing, and may provide a novel, low-cost, safe approach to improving skin wound repair in the stressed individual.